Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

Figure 1

Panitumumab inhibited ligand-induced pEGFR in vitro and in vivo. Immunoprecipitation of both phospho- and total- EGFR harvested from (A) panitumumab-treated A431 epidermoid carcinoma cells in vitro 15 minutes after a treatment with EGF and (B) panitumumab-treated A431 xenograft tumors 30 minutes after an intraperitoneal injection of EGF.

Back to article page

Molecular Cancer

ISSN: 1476-4598